{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263534","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.440837+00:00","generated_at":"2026-05-17T00:40:42.080838+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA","bullets":["First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.","Part 1: 80 adults with confirmed EoE and dysphagia randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks.","Part 2: open-label 12-week extension where all patients receive VOQUEZNA 20 mg daily.","Topline results from primary and secondary endpoints are anticipated in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263534","json":"https://secwatch.observer/filing/0001193125-25-263534.json","markdown":"https://secwatch.observer/filing/0001193125-25-263534.md","text":"https://secwatch.observer/filing/0001193125-25-263534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/0001193125-25-263534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:40:42.080838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}